Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium

Rhea-AI Summary

Kane Biotech Inc. announces the presentation of its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The gel, featuring thermo-reversible properties, is designed for sensitive wounds such as burns and offers prolonged antimicrobial activity in a moist environment. Dr. Gregory Schultz, Chief Scientific Officer, expresses excitement for the presentation and anticipates a positive reception within the wound care community.

WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.

The international conference will take place from January 27 to February 1, 2024 in Maui, Hawaii and covers the latest advancements in wound healing, burn care, and infection control. During this conference, Kane Biotech will present along with other important voices involved in the care of soft tissue injuries and related complications.

“I’m excited to be presenting Kane’s revyve™ Antimicrobial Wound Gel to the wound care community at the Boswick conference and believe it will be very well-received, particularly by practitioners focused on burn care. With its thermo-reversible properties, the gel is easy to apply, stays on the wound and is easily rinsed off with cold water making it ideal for sensitive wounds such as burns,” stated Dr. Gregory Schultz, Chief Scientific Officer of Kane Biotech. “The Wound Gel, which is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic Pluronic surfactant, provides prolonged antimicrobial activity in a moist environment best suited for wound healing.”

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB^®, Aledex™, bluestem™, bluestem^®, silkstem™, goldstem™, coactiv+™, coactiv+^®, DermaKB™, DermaKB Biofilm™ and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:
Marc Edwards			Ray Dupuis	Nicole Sendey
Chief Executive Officer			Chief Financial Officer	Investor Relations/PR
Kane Biotech Inc.			Kane Biotech Inc.	Kane Biotech Inc.
medwards@kanebiotech.com			rdupuis@kanebiotech.com	nsendey@kanebiotech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

FAQ

What is Kane Biotech presenting at the Boswick Burn and Wound Care Symposium?

Kane Biotech is presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.

When and where will the Boswick Burn and Wound Care Symposium take place?

The Boswick Burn and Wound Care Symposium will take place from January 27 to February 1, 2024, in Maui, Hawaii.

Who will be presenting alongside Kane Biotech at the conference?

Kane Biotech will present along with other important voices involved in the care of soft tissue injuries and related complications.

What are the key features of the revyve™ Antimicrobial Wound Gel?

The revyve™ Antimicrobial Wound Gel features thermo-reversible properties, making it easy to apply, stay on the wound, and be easily rinsed off with cold water. It offers prolonged antimicrobial activity in a moist environment.

Who expressed excitement for the presentation at the Boswick conference?

Dr. Gregory Schultz, Chief Scientific Officer of Kane Biotech, expressed excitement for the presentation and believes the gel will be well-received by the wound care community.